Strategy has completed its 100th bitcoin acquisition since adopting the cryptocurrency as its primary reserve asset in 2020, purchasing 592 BTC for roughly $39.8 million at an average price of $67,286 per coin.

The purchase was funded through the sale of 297,940 shares of its Class A common stock via its at-the-market offering program between February 17–22, generating $39.7 million in net proceeds, according to a company statement. 

Including this latest acquisition, Strategy now holds 717,722 bitcoin, acquired for an aggregate $54.56 billion at an average price of $76,020 per bitcoin, making it the largest corporate bitcoin treasury in the world.

The company still has $37.4 billion in securities available for future issuance under its at-the-market program, including $7.8 billion of MSTR stock and $20.3 billion of STRK stock. 

Strategy maintains a public dashboard detailing its bitcoin holdings, purchases, and market prices in compliance with Regulation FD.

The timing of the purchase coincides with renewed weakness in bitcoin, which dropped from around $68,000 over the weekend to near $66,000, putting pressure on MSTR shares. The stock has fallen more than 2% to around $128 in premarket, reflecting the strong correlation between Strategy’s bitcoin exposure and its share price.

Michael Saylor, Executive Chairman, hinted at the purchase on X, posting the company’s bitcoin tracker with the caption “The Orange Century,” signaling the milestone 100th acquisition.

Last week, Strategy purchased $168.4 million in bitcoin, adding 2,486 BTC to bring its total holdings to 717,131 bitcoin at the time. 

Strategy isn’t selling any bitcoin

Earlier this year, Michael Saylor defended Strategy’s approach of regularly buying bitcoin, insisting the company has no plans to sell its holdings even during prolonged market downturns. 

He argued that fears about leverage and liquidity pressures were unfounded, noting the company has sufficient cash to cover dividends and debt for over two years. 

“We’re not going to be selling; we’re going to be buying bitcoin,” Saylor said. “I expect we’ll buy bitcoin every quarter forever.”

At the time of writing, bitcoin is trading near $66,000 and shares of Strategy are at $127.90 in pre-market. 

According to BitcoinTreasuries.net’s January 2026 report, Strategy accounted for over 90% of net new corporate purchases, acquiring 40,150 BTC and ending the month with 712,647 BTC.

Its buying made up 93% of public-company gross purchases and 97.5% of net additions, single-handedly bringing sector-wide accumulation back to late-summer levels.

HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”) powered medical technology company focused on advancing the capabilities of ECGs/EKGs for the earlier detection of heart disease, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Device designation for its Aortic Stenosis (“AS”) ECG algorithm.

Aortic Stenosis is one of the most serious and common heart valve diseases, often progressing silently and leading to severe, life-threatening outcomes if left undetected. Early symptoms are frequently vague or absent, resulting in delayed diagnosis and treatment. If unrecognized, AS can cause irreversible myocardial damage and significant deterioration in cardiac function.

The algorithm would offer a novel, AI-driven ECG solution capable of detecting moderate-to-severe aortic stenosis. Once cleared by the FDA, the algorithm will be accessible through HeartSciences’ MyoVista Insights cloud-based platform which would directly integrate with hospital electronic health record (“EHR”) systems, requiring no additional hardware or testing. This technology provides several key clinical advantages:

• Detection in asymptomatic or under-evaluated patients who may not yet show signs of AS.
• Real-time or retrospective analysis using existing ECG data already captured during routine care.
• Expanded access to early diagnosis, especially in underserved areas lacking specialized cardiac imaging or providers.

The algorithm was developed using advanced convolutional neural network (CNN) deep learning techniques and trained on more than 120,000 ECG records. In performance evaluations, it demonstrated the ability to detect aortic stenosis up to 24 months prior to confirmatory echocardiography, with diagnostic accuracy (AUROC) increasing as the disease progressed.

This breakthrough gives clinicians the ability to identify aortic valve disease earlier in its course, allowing for timely interventions and improved patient outcomes. The AI-ECG algorithm was developed at the Icahn School of Medicine at Mount Sinai by Dr. Akhil Vaid.

“Receiving FDA Breakthrough Device Designation marks another significant milestone for HeartSciences,” said Andrew Simpson, CEO of HeartSciences. “By combining the widespread accessibility of ECGs with the power of deep learning, our aortic stenosis algorithm has the potential to transform how this serious and often silent disease is detected—leading to earlier referrals, better treatment pathways, and ultimately, improved lives.”

About HeartSciences

HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve ECG’s clinical utility. Millions of ECGs are performed every week and the Company’s objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings….